These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2774869)

  • 1. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 3. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].
    Oelschläger H; Hellwich KH; Rothley D
    Arch Pharm (Weinheim); 1994 Apr; 327(4):261-5. PubMed ID: 8204026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Conjugation reactions of ciprofibrate with human and laboratory animals].
    Oelschläger H; Müller D; Hellwich KH; Ueberall S; Seeling A; Machts H; Hofmann B; Glöckner R
    Arzneimittelforschung; 2003; 53(4):247-53. PubMed ID: 12785120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ciprofibrate on gastric secretion in the rat.
    Eason CT; Pattison A; Howells DD; Bonner FW
    J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ciprofibrate and clofibric acid as peroxisomal proliferators in primary cultures of rat hepatocytes.
    Feller DR; Singh Y; Shirhatti VR; Kocarek TA; Liu CT; Krishna G
    Hepatology; 1987; 7(3):508-16. PubMed ID: 3570161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amino acid derivatives of 2-(p-chlorophenoxy)-2-methylpropionic acid as compounds with potential antilipemic agents. II. Preparation of methyl esters of N-[2-(p-chlorophenoxy)-2-methylpropionyl] amino acids].
    Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1987; 44(2):121-31. PubMed ID: 3434313
    [No Abstract]   [Full Text] [Related]  

  • 11. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
    Awasthi YC; Singh SV; Goel SK; Reddy JK
    Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pharmacokinetics of antilipemic agents. 8. Unequivocal characterization of ciprofibrate-O-beta-d-glucuronide].
    Oelschläger H; Kohl C; Armstrong DW; Rothley D
    Arch Pharm (Weinheim); 1991 Aug; 324(8):505-8. PubMed ID: 1781732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
    Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
    Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of ciprofibrate in human plasma by high-performance liquid chromatography.
    Park GB; Biddlecome CE; Koblantz C; Edelson J
    J Chromatogr; 1982 Feb; 227(2):534-9. PubMed ID: 7061664
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
    Srinivasan SR; Chow CK; Glauert HP
    Toxicology; 1990 Jun; 62(3):321-32. PubMed ID: 2389247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate.
    Spencer AJ; Barbolt TA; Henry DC; Eason CT; Sauerschell RJ; Bonner FW
    Toxicol Pathol; 1989; 17(1 Pt 1):7-15. PubMed ID: 2501865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achiral and chiral determination of ciprofibrate and its glucuronide in human urine by capillary electrophoresis.
    Hüttemann H; Blaschke G
    J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):33-41. PubMed ID: 10410925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo distribution of a carcinogenic hepatic peroxisome proliferator: whole-body autoradiography of [14C]ciprofibrate in the mouse.
    Waddell WJ; Marlowe C; Rao MS; Reddy JK
    Carcinogenesis; 1989 Jan; 10(1):221-3. PubMed ID: 2910527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.